中华检验医学杂志
中華檢驗醫學雜誌
중화검험의학잡지
CHINESE JOURNAL OF LABORATORY MEDICINE
2013年
11期
1008-1012
,共5页
王敏%吕萌%史小芹%鲁清月%付光宇%杨增利
王敏%呂萌%史小芹%魯清月%付光宇%楊增利
왕민%려맹%사소근%로청월%부광우%양증리
肺肿瘤%癌,小细胞%癌,非小细胞肺%肽碎片%重组蛋白质类%磷酸丙酮酸水合酶%肿瘤标记,生物学
肺腫瘤%癌,小細胞%癌,非小細胞肺%肽碎片%重組蛋白質類%燐痠丙酮痠水閤酶%腫瘤標記,生物學
폐종류%암,소세포%암,비소세포폐%태쇄편%중조단백질류%린산병동산수합매%종류표기,생물학
Lung neoplasms%Carcinoma,small cell%Carcinoma,non-small-cell lung%Peptide fragments%Recombinant proteins%Phosphopyruvate hydratase%Tumor markers,biological
目的 探讨pro-GRP与NSE水平对SCLC临床诊断、疗效监测的意义及治疗后标志物水平与生存期的关系.方法 回顾性研究.收集2008年5月1日至2011年4月30日由郑州人民医院确诊的41例SCLC(男30例,女11例,年龄46 ～ 78岁)、95例NSCLC(男55例,女40例,年龄42～88岁)和127名健康人(男80名,女47名,年龄35～ 78岁)样本,检测pro-GRP和NSE的血清学水平,分析评价2项指标在SCLC患者治疗前后的水平变化.采用SPSS 16.0单因素方差分析、随机区组设计的方差分析和log-rank test进行统计分析.结果 SCLC患者治疗前血清pro-GRP中位数水平为357.8 ng/L,NSE治疗前中位数水平为89.5 μg/L,两者均显著高于NSCLC组指标的中位数水平(pro-GRP:39.9 ng/L; NSE:11.43 μg/L)和健康人组指标的中位数水平(pro-GRP:12.7 ng/L; NSE:10.03 μg/L)(F值分别为41.05、100.42,P均＜0.001).pro-GRP和NSE诊断SCLC的敏感度分别为80.4％和78.0％,特异度分别为92％和87％;两指标血清水平上相关性较低(r=0.2750),联合检测SCLC敏感度可达95％,特异度可达85％;SCLC-LD患者治疗前、后pro-GRP水平的差异有统计学意义(F=3.53,P=0.038),NSE的水平在SCLC-ED患者治疗前、后的差异有统计学意义(F=16.049,P =0.000).部分缓解的SCLC患者治疗后NSE水平低于界值的患者生存期长于高于界值的患者(P =0.001).结论 pro-GRP和NSE联合检测诊断SCLC的灵敏度优于单指标;pro-GRP水平更能反映SCLC-LD患者的治疗效果,NSE水平则更能反映SCLC-ED患者的治疗效果.治疗后NSE水平对评估部分缓解患者的生存期有一定价值.
目的 探討pro-GRP與NSE水平對SCLC臨床診斷、療效鑑測的意義及治療後標誌物水平與生存期的關繫.方法 迴顧性研究.收集2008年5月1日至2011年4月30日由鄭州人民醫院確診的41例SCLC(男30例,女11例,年齡46 ～ 78歲)、95例NSCLC(男55例,女40例,年齡42～88歲)和127名健康人(男80名,女47名,年齡35～ 78歲)樣本,檢測pro-GRP和NSE的血清學水平,分析評價2項指標在SCLC患者治療前後的水平變化.採用SPSS 16.0單因素方差分析、隨機區組設計的方差分析和log-rank test進行統計分析.結果 SCLC患者治療前血清pro-GRP中位數水平為357.8 ng/L,NSE治療前中位數水平為89.5 μg/L,兩者均顯著高于NSCLC組指標的中位數水平(pro-GRP:39.9 ng/L; NSE:11.43 μg/L)和健康人組指標的中位數水平(pro-GRP:12.7 ng/L; NSE:10.03 μg/L)(F值分彆為41.05、100.42,P均＜0.001).pro-GRP和NSE診斷SCLC的敏感度分彆為80.4％和78.0％,特異度分彆為92％和87％;兩指標血清水平上相關性較低(r=0.2750),聯閤檢測SCLC敏感度可達95％,特異度可達85％;SCLC-LD患者治療前、後pro-GRP水平的差異有統計學意義(F=3.53,P=0.038),NSE的水平在SCLC-ED患者治療前、後的差異有統計學意義(F=16.049,P =0.000).部分緩解的SCLC患者治療後NSE水平低于界值的患者生存期長于高于界值的患者(P =0.001).結論 pro-GRP和NSE聯閤檢測診斷SCLC的靈敏度優于單指標;pro-GRP水平更能反映SCLC-LD患者的治療效果,NSE水平則更能反映SCLC-ED患者的治療效果.治療後NSE水平對評估部分緩解患者的生存期有一定價值.
목적 탐토pro-GRP여NSE수평대SCLC림상진단、료효감측적의의급치료후표지물수평여생존기적관계.방법 회고성연구.수집2008년5월1일지2011년4월30일유정주인민의원학진적41례SCLC(남30례,녀11례,년령46 ～ 78세)、95례NSCLC(남55례,녀40례,년령42～88세)화127명건강인(남80명,녀47명,년령35～ 78세)양본,검측pro-GRP화NSE적혈청학수평,분석평개2항지표재SCLC환자치료전후적수평변화.채용SPSS 16.0단인소방차분석、수궤구조설계적방차분석화log-rank test진행통계분석.결과 SCLC환자치료전혈청pro-GRP중위수수평위357.8 ng/L,NSE치료전중위수수평위89.5 μg/L,량자균현저고우NSCLC조지표적중위수수평(pro-GRP:39.9 ng/L; NSE:11.43 μg/L)화건강인조지표적중위수수평(pro-GRP:12.7 ng/L; NSE:10.03 μg/L)(F치분별위41.05、100.42,P균＜0.001).pro-GRP화NSE진단SCLC적민감도분별위80.4％화78.0％,특이도분별위92％화87％;량지표혈청수평상상관성교저(r=0.2750),연합검측SCLC민감도가체95％,특이도가체85％;SCLC-LD환자치료전、후pro-GRP수평적차이유통계학의의(F=3.53,P=0.038),NSE적수평재SCLC-ED환자치료전、후적차이유통계학의의(F=16.049,P =0.000).부분완해적SCLC환자치료후NSE수평저우계치적환자생존기장우고우계치적환자(P =0.001).결론 pro-GRP화NSE연합검측진단SCLC적령민도우우단지표;pro-GRP수평경능반영SCLC-LD환자적치료효과,NSE수평칙경능반영SCLC-ED환자적치료효과.치료후NSE수평대평고부분완해환자적생존기유일정개치.
Objective To study the serum levels of progastrin-releasing peptide (pro-GRP) and neuron-specific enolase (NSE) for the clinical diagnosis,therapy monitoring and survival time analysis of small cell lung cancer (SCLC).Methods All 41 SCLC samples (30 males,11 females,age range from 46 to 78 years),95 NSCLC samples (55 males,40 females,age range from 42 to 88 years),and 127 normal individuals samples (80 males,47 females,age range from 35 to 78 years) which were diagnosed by People's Hospital of Zhengzhou from May 1,2008 to April 30,2011 were collected.Serum levels of pro-GRP,NSE and their changes in SCLC patients before and after therapy were evaluated.ANOVA analysis,randomized block design analysis of variance and the log-rank test were collected SPSS 16.0 to evaluate the survival time.Results The serum levels of pro-GRP (median 357.8 ng/L) and NSE (median 89.5 μg/L) in SCLC group were significantly higher than those in the NSCLC group (pro-GRP:39.9 ng/L;NSE:11.43 μg/L) and normal individuals group (pro-GRP:12.7 ng/L;NSE:10.03 μg/L) (P=0.000).The sensitivity of pro-GRP and NSE for the diagnosis of SCLC were 80.4％ and 78.0％,while the specificity were 92％ and 87％,respectively.There is a poor correlation between pro-GRP and NSE serum levels,but when combined the sensitivity can be 95％ and specificity can be 85％.Significantly statistical difference of pro-GRP levels was observed in the different stages of treatment (before and after therapy) in SCLC-LD patients (F =3.53,P =0.038),and significant statistical difference of NSE levels was also observed in SCLC-ED patients in different stages (F =16.049,P =0.000).In partied response SCLC patients,the group with NSE level lower than cut-off value had longer survival time than the other group with NSE level higher than cut-off value (P =0.001).Conclusions The sensitivity of the combined analysis of pro-GRP and NSE is better than single marker for the diagnosis of SCLC.The serum level of pro-GRP has better correlation with therapeutic effect of SCLC-LD patient than NSE.The serum level of NSE are well correlated with therapeutic effect in SCLC-ED patients.There are some certain value of NSE level for evaluation the survival time of SCLC patients who were in partial response.
